{"name":"SK Bioscience","slug":"sk-bioscience","ticker":"302440.KS","exchange":"KRX","domain":"skbioscience.co.kr","description":"SK Bioscience (Korean: SK바이오사이언스) is a South Korean biotechnology company that produces vaccines and other products and is a subsidiary of SK Chemicals.","hq":"Seongnam, South Korea","founded":2010,"employees":"~1,000","ceo":"Jae Yong Ahn","sector":"Vaccines / CDMO","stockPrice":43200,"stockChange":2050,"stockChangePercent":4.98,"marketCap":"$2.3B","metrics":{"revenue":436623723.0385333,"revenueGrowth":17.4,"grossMargin":11.5,"rdSpend":0,"netIncome":-38492646.901707985,"cash":607509567.2929322,"dividendYield":0,"peRatio":-47.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"COVID-19 vaccine patent cliff ($0.0B at risk)","drug":"COVID-19 vaccine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"GBP560-B","genericName":"GBP560-B","slug":"gbp560-b","indication":"Other","status":"phase_1"},{"name":"IMOJEV","genericName":"IMOJEV","slug":"imojev","indication":"Prevention of Japanese encephalitis in endemic regions","status":"phase_3"},{"name":"IXIARO","genericName":"IXIARO","slug":"ixiaro","indication":"Other","status":"marketed"},{"name":"NBP608 (Low Potency)","genericName":"NBP608 (Low Potency)","slug":"nbp608-low-potency","indication":"Other","status":"phase_3"},{"name":"SKYVaricella®","genericName":"SKYVaricella®","slug":"skyvaricella","indication":"Prevention of varicella (chickenpox) in children and adults","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GBP510 adjuvanted with AS03","genericName":"GBP510 adjuvanted with AS03","slug":"gbp510-adjuvanted-with-as03","indication":"Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NBP608 (Mid Potency)","genericName":"NBP608 (Mid Potency)","slug":"nbp608-mid-potency","indication":"Inflammatory skin conditions (dermatitis, eczema, psoriasis)","status":"phase_3"}]}],"pipeline":[{"name":"GBP510 adjuvanted with AS03","genericName":"GBP510 adjuvanted with AS03","slug":"gbp510-adjuvanted-with-as03","phase":"phase_3","mechanism":"GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.","indications":["Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)"],"catalyst":""},{"name":"GBP560-B","genericName":"GBP560-B","slug":"gbp560-b","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMOJEV","genericName":"IMOJEV","slug":"imojev","phase":"phase_3","mechanism":"IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection.","indications":["Prevention of Japanese encephalitis in endemic regions"],"catalyst":""},{"name":"IXIARO","genericName":"IXIARO","slug":"ixiaro","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"NBP608 (Low Potency)","genericName":"NBP608 (Low Potency)","slug":"nbp608-low-potency","phase":"phase_3","mechanism":"NBP608 is a low-potency compound developed by SK Bioscience with an undisclosed mechanism of action currently in phase 3 clinical development.","indications":[],"catalyst":""},{"name":"NBP608 (Mid Potency)","genericName":"NBP608 (Mid Potency)","slug":"nbp608-mid-potency","phase":"phase_3","mechanism":"NBP608 is a mid-potency corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses.","indications":["Inflammatory skin conditions (dermatitis, eczema, psoriasis)","Allergic and inflammatory disorders"],"catalyst":""},{"name":"SKYVaricella®","genericName":"SKYVaricella®","slug":"skyvaricella","phase":"marketed","mechanism":"SKYVaricella® is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection.","indications":["Prevention of varicella (chickenpox) in children and adults"],"catalyst":""}],"recentEvents":[{"date":"2023-02-15","type":"regulatory","headline":"SK Bioscience's COVID-19 vaccine receives WHO prequalification","summary":"The World Health Organization (WHO) has prequalified SK Bioscience's COVID-19 vaccine, allowing it to be included in the WHO's list of approved vaccines for global distribution.","drugName":"","sentiment":"positive"},{"date":"2022-06-30","type":"earnings","headline":"SK Bioscience reports Q2 2022 earnings","summary":"SK Bioscience announced its Q2 2022 earnings, reporting a revenue increase of 15% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2021-12-17","type":"deal","headline":"SK Bioscience partners with Pfizer to develop COVID-19 vaccine","summary":"SK Bioscience partnered with Pfizer to develop a COVID-19 vaccine, expanding its capabilities in vaccine development.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQcFFZVGJUN2k3VkFyZWJpbzhJdklueUtIaHJvaWJZZHRaUXozWkVpZEd2VUlrQ0M2dnBiVGRsTFVzMWpIamVCNmEyY0FudHJFYXJ2Y21IOGhVODVYM1hHaGVTbkpQa244dkt5STQ5NGExWFhTVHZqNXJVMHllOFR3cFJjRXpYOWFqanBlY25ucw?oc=5","date":"2026-03-18","type":"pipeline","source":"Yahoo! Finance Canada","summary":"SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support - Yahoo! Finance Canada","headline":"SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support - Yahoo! Fina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVjd1YUJGS2FwQTJKTHdYNFl2R0RPa0EyUHRvUlNHRWFQRmFRTWV3dUxLVFU5RGYySkRzWVJ2eGpnbkNvVmsyUTlDWV9rZEpoRHlaN09XMm1jUzVnUnR1Z0xoa2dpOGJlbGhTcVVqRGJEZXUyMXgyRGFYSVdiSXhIN0QxVHdUdUFVTnlF?oc=5","date":"2026-02-03","type":"deal","source":"Yahoo Finance","summary":"SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute - Yahoo Finance","headline":"SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPY0tpTlFTcWFINXZlU1B4ekFDOHBfa09wVWM3U0xnQURIU25MYmJRdFBDdFFObEJVcW5hQ0VqazlPbG1QbkVtTFZxVGVIVjE5aGwzcUlvVVRPWnJ2UFd6blJld1NRYW9aSk5WZ0J4OS1ZSGhOcHhFdmpZNndWRlBaY1k2MmFKQ2xwUG5sTGVB?oc=5","date":"2026-01-22","type":"regulatory","source":"Yahoo Finance","summary":"SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding - Yahoo Finance","headline":"SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZEZwQVJyNkN6SVZWa2dkc0lnUVhmSE8tU1VxLTlBQVRVdkZXODFiWEtMNUdkZHZHZzN4dEpkd3ZvS3BadTQ0MURyUWN0SWhNWFFXV3VLcWlvdXdEV1VMcy11NUhRcE9wR2haOUhfMktkX3IxRnZESVRLZV9LWlBUQXVpYjFmWTcyRFFNLS1rSXlDYTd5dGlTTk1ZVXBOdi1VQlE?oc=5","date":"2026-01-21","type":"pipeline","source":"Seoul Economic Daily","summary":"SK Bioscience Creates COO Position, Hires Samsung Biologics, Hanmi Veterans - Seoul Economic Daily","headline":"SK Bioscience Creates COO Position, Hires Samsung Biologics, Hanmi Veterans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNT2hDSkd1eC1yRm9QQmpUbG1naWU3cU5UZjhYOGU3cHpLV1Nkb1FQRjc2VEw3eVVRbzQ2QU8zd1N3NE5ORElpQWlUX1ZLU1kyOFRGLS1Dc21la0JxSVhVOTh4WGNFZzBFNHpHWE50eVpyLTFIa1diU0tMOHR1S0g5V2FqdHhJV0pXYVlGNUdueVNOMDRzSjZyNk5CLUhpdUJRaTV4T09GbUdER1dVSnMxaHhUakZNajc4TTRIZVZ6VVBoNzNHQWl1dmp3?oc=5","date":"2022-06-29","type":"regulatory","source":"Reuters","summary":"S.Korea approves first domestically developed COVID vaccine - Reuters","headline":"S.Korea approves first domestically developed COVID vaccine","sentiment":"positive"}],"patents":[{"drugName":"COVID-19 vaccine","drugSlug":"covid-19-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_1":1,"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BIOENTECH","MODERNA","PFIZER"],"therapeuticFocus":["Infectious diseases","Vaccines"],"financials":{"source":"yahoo_finance","revenue":436623729.2175218,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":436623729.2175218},{"period":"2024-12-31","value":179340181.99261495},{"period":"2023-12-31","value":247686114.33459356},{"period":"2022-12-31","value":306151435.5065771}],"grossProfit":50893334.83680657,"grossProfitHistory":[{"period":"2025-12-31","value":50893334.83680657},{"period":"2024-12-31","value":20763543.711279422},{"period":"2023-12-31","value":95347867.81116363},{"period":"2022-12-31","value":160615455.12737963}],"rdSpend":46829064.169382304,"rdSpendHistory":[{"period":"2025-12-31","value":46829064.169382304},{"period":"2024-12-31","value":47829054.1690078},{"period":"2023-12-31","value":57475329.403263204},{"period":"2022-12-31","value":38851375.929216504}],"sgaSpend":32320810.4291904,"operatingIncome":-82785363.70590484,"operatingIncomeHistory":[{"period":"2025-12-31","value":-82785363.70590484},{"period":"2024-12-31","value":-92792949.46436039},{"period":"2023-12-31","value":-8035611.129972271},{"period":"2022-12-31","value":77095663.47754481}],"netIncome":-38492646.68452505,"netIncomeHistory":[{"period":"2025-12-31","value":-38492646.68452505},{"period":"2024-12-31","value":-36117521.31989053},{"period":"2023-12-31","value":14959962.223499373},{"period":"2022-12-31","value":82081709.43759276}],"eps":-698,"epsHistory":[{"period":"2024-12-31","value":-698},{"period":"2023-12-31","value":290},{"period":"2022-12-31","value":1590},{"period":"2021-12-31","value":4810}],"cash":70753971.46533273,"cashHistory":[{"period":"2025-12-31","value":70753971.46533273},{"period":"2024-12-31","value":209609354.2884562},{"period":"2023-12-31","value":85147534.07496265},{"period":"2022-12-31","value":151014164.31068528}],"totalAssets":1981287190.7830286,"totalLiabilities":615545575.7604243,"totalDebt":315041074.91678077,"equity":1199064209.4103305,"operatingCashflow":68712349.34641734,"operatingCashflowHistory":[{"period":"2025-12-31","value":68712349.34641734},{"period":"2024-12-31","value":-85813984.04853682},{"period":"2023-12-31","value":19671385.135154754},{"period":"2022-12-31","value":-83761749.78154753}],"capex":-174538686.46725112,"capexHistory":[{"period":"2025-12-31","value":-174538686.46725112},{"period":"2024-12-31","value":-115445318.37238695},{"period":"2023-12-31","value":-33713956.60069978},{"period":"2022-12-31","value":-51272227.76746501}],"freeCashflow":-105826337.12083378,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":10277599.8833287,"ebit":-12922333.146903818,"ebitda":4307708.746664584,"period":"2025-12-31","revenue":123463342.41708338,"epsBasic":null,"netIncome":-38852878.76139037,"rdExpense":11895107.9983606,"epsDiluted":null,"grossProfit":3326157.933471984,"operatingIncome":-34594891.43340922},{"sga":8305359.6414568005,"ebit":-8656283.311362011,"ebitda":6504896.065785689,"period":"2025-09-30","revenue":101060308.31277545,"epsBasic":313,"netIncome":16408482.857577005,"rdExpense":13322963.7968492,"epsDiluted":313,"grossProfit":22073781.832456432,"operatingIncome":-12984714.67500137},{"sga":6829257.726510701,"ebit":-22043708.01543958,"ebitda":-7616524.508838778,"period":"2025-06-30","revenue":108497305.80139932,"epsBasic":-210,"netIncome":-11043892.518668257,"rdExpense":13569017.314988201,"epsDiluted":-210,"grossProfit":7975464.3338356875,"operatingIncome":-25066558.337044913},{"sga":6265436.080780501,"ebit":-7630769.403468771,"ebitda":6560202.18946443,"period":"2025-03-31","revenue":103602772.69296685,"epsBasic":-95,"netIncome":-5004358.255340249,"rdExpense":8041975.059184301,"epsDiluted":-95,"grossProfit":17517930.74374564,"operatingIncome":-10139199.253746161},{"sga":12045491.763402501,"ebit":-12583396.453378389,"ebitda":1905989.854511613,"period":"2024-12-31","revenue":105138811.99680005,"epsBasic":null,"netIncome":-4314917.309694498,"rdExpense":9576064.817722,"epsDiluted":null,"grossProfit":3765991.604660415,"operatingIncome":-34036040.17331499},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-290,"netIncome":null,"rdExpense":null,"epsDiluted":-290,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":43200,"previousClose":41150,"fiftyTwoWeekHigh":61300,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.0 - 61300.0","fiftyDayAverage":42903,"twoHundredDayAverage":48049.25,"beta":0.93,"enterpriseValue":2037718242.856613,"forwardPE":-47.8,"priceToBook":0,"priceToSales":5.2,"enterpriseToRevenue":4.67,"enterpriseToEbitda":-93.58,"pegRatio":0,"ebitda":-21775987.906765416,"ebitdaMargin":-5,"freeCashflow":-103767275.55545662,"operatingCashflow":68712346.95070188,"totalDebt":315041066.34878,"debtToEquity":23.1,"currentRatio":3.82,"returnOnAssets":-2.7,"returnOnEquity":-2.8,"analystRating":"4.0 - Underperform","recommendationKey":"underperform","numberOfAnalysts":5,"targetMeanPrice":37800,"targetHighPrice":55000,"targetLowPrice":23000,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":68.9,"institutionHeldPercent":3.4,"sharesOutstanding":78434701,"floatShares":25941493,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":8311.88,"bookValue":0,"officers":[{"age":58,"name":"Mr. Jae-Yong  Ahn","title":"CEO, President & Director"},{"age":null,"name":"Dr. Sally  Choe","title":"Head of Global Clinical Development & Regulatory Affairs"},{"age":55,"name":"Ki-seok  Song","title":"Value Innovation Director"},{"age":52,"name":"Jin-seon  Park","title":"Head of Marketing & Business Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.skbioscience.co.kr","phone":"82 2 2008 2200"}}